Arab Strategy Forum to Focus on Intellectual Property Rights

October 26, 2009

The Mohammed bin Rashid Al Maktoum Foundation has announced that 30 intellectuals and 200 thought-leaders will provide critical insights into the state of intellectual property rights and its role in the region’s economy, at the first in a series of seminars to mark the Arab Strategy Forum, a crucial platform for policy makers to network and share expertise on economic, geopolitical, social and cultural issues.

To be held in Dubai, the session titled ‘Transfer or indigenisation (sic) of knowledge?’ will define the second day of the event that will be held on 28th and 29th of October.

The discussions will apparently throw light on the legislative, organizational, cultural, and material requirements for intellectual property rights and will specifically examine the extent of Arab contributions to the development of the international conventions on property rights.

For more information: http://www.ameinfo.com/213654.html

We wonder if our good friend Dr. Amir Khoury of Tel Aviv University will attend and hope the event does not turn into another fiasco trying to copyright Hummous and the pyramids.

Come to think of it, as of tomorrow, I am expecting to pass the 100,000 reader mark on this blog, which makes me far and away the region’s most popular writer on IP issues. Although, not a major IP writer by Jewish standards, with a much smaller readership than either, say, Professor David Nimmer or Professor Jeremy Philips, nevertheless, as the Middle East’s number 1 IP blogger, who faithfully tries to cover IP events in Arab countries, I’d have expected an all expense paid, complimentary trip  to this conference. Ah well.

Still, it would be nice if the Arab States decide to allow Israeli companies to register trademarks there. It would be nice if, 15 years after signing a peace treaty, Jordan would allow Israeli companies to register patents…


Teva fails to invalidate Vigamox

October 26, 2009

U.S. District Judge Sue L. Robinson (Delaware) ruled last week that Israel’s Teva Pharmaceuticals infringed the patents for Vigamox and failed to prove the patents invalid. Vigamox is used to treat eye infections and is made by Nestle’s Alcon unit. Teva challenged the validity of the patent in 2006. If it had been successful, Teva would have been able to launch its own competing product in 2014, six years before the expiration of the Vigamox patent.